生物活性 | |||
---|---|---|---|
描述 | KJ Pyr 9 (KJ-Pyr-9) acts by disrupting the MYC-MAX complex formation within cells, as observed in protein fragment complementation assays[1]. KJ Pyr 9 specifically targets and inhibits MYC-induced oncogenic transformation in cell cultures, showing minimal or negligible impact on the oncogenic functions of various unrelated oncoproteins[1]. KJ Pyr 9 notably affects the proliferation of cells overexpressing MYC, both human and avian, and distinctively reduces the transcriptional signature driven by MYC[1]. KJ Pyr 9 efficacy has been tested against three cell lines known for their dependence on enhanced MYC activity: NCI-H460, MDA-MB-231, and SUM-159PT, successfully inhibiting their proliferation with IC50 values ranging between 5 and 10 μM[1]. Burkitt lymphoma cell lines, characterized by constitutively high c-MYC expression, show even greater sensitivity to KJ Pyr 9, with IC50 values between 1 and 2.5 μM[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.59mL 0.52mL 0.26mL |
12.97mL 2.59mL 1.30mL |
25.95mL 5.19mL 2.59mL |
参考文献 |
---|